Three-dimensional right ventricular free-wall strain for identifying a higher Doppler-estimated PASP subgroup in high-altitude heart disease - Summary - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Utilizing Three-Dimensional Right Ventricular Free-Wall Strain to Distinguish a Subgroup with Elevated Doppler-Estimated Pulmonary Artery Systolic Pressure in High-Altitude Heart Disease
To determine whether three-dimensional speckle-tracking-derived right ventricular free-wall longitudinal strain (absolute RVFWLS) better identifies a subgroup of patients with elevated Doppler-estimated pulmonary artery systolic pressure (PASP ≥60 mmHg) within high-altitude heart disease (HAHD) compared to TAPSE.
Approach:
Study Design: Retrospective study involving 100 participants (40 controls, 60 HAHD patients) who underwent standardized echocardiography.
Subgroup Classification: Patients with HAHD were categorized into higher-PASP (PASP ≥60 mmHg) and lower-PASP (PASP <60 mmHg) subgroups.
Statistical Analysis: ROC curves were compared using paired DeLong tests; logistic models evaluated absolute RVFWLS beyond TAPSE, age, and sex.
Key Findings:
Absolute RVFWLS showed better discrimination than TAPSE for identifying the higher-PASP subgroup, with ROC AUC values of 0.886 and 0.647, respectively (P = 0.002).
Incorporating absolute RVFWLS into the model with TAPSE, age, and sex significantly improved model fit (likelihood-ratio P < 0.001).
RV-ESV accounted for 45.0% of the PASP–3D-EF association but did not materially account for the PASP–absolute RVFWLS association.
Interpretation:
Three-dimensional absolute RVFWLS is more effective than TAPSE in identifying higher-PASP subgroups in HAHD.
Limitations:
Findings are exploratory and require prospective validation against invasive hemodynamic measurements.
Study is retrospective and may be subject to selection bias.
Conclusion:
Absolute RVFWLS is a superior echocardiographic measure for identifying higher-PASP in HAHD compared to TAPSE.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
Ahead of ISC2026 in Prague, Jennifer Van Eyk explains how scalable LC-MS workflows and single-cell proteomics are helping reveal the biological differences that could make precision medicine a clinical reality